The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
TRHC - Q4 expectation:
For the full year 2020 ending December 31, we expect:
Revenue in the range of $294 million to $296 million, the mid-point of which represents 4% growth compared to the full year 2019, and fourth quarter revenue to increase 5% to 8% as compared to the third quarter through a combination of organic growth and our October acquisition of Personica. The key factors influencing our guidance are: (i) the aforementioned CMR restrictions and (ii) the negative impact from COVID-19 on medication adherence initiatives, which are seasonally weighted toward the second half of the calendar year.
GAAP net loss in the range of $68.8 million to $67.9 million.
Non-GAAP Adjusted EBITDA in the range of $21 million to $22 million with fourth quarter non-GAAP Adjusted EBITDA in the range of $4 million to $5 million.
2021 Outlook
We plan to provide formal guidance following our fourth quarter and full year 2020 results. Currently, we believe that overall revenue can grow at 20% in 2021 as compared to the mid-point of our 2020 guidance. At present, our confidence in our growth outlook is based on: (i) positive PACE enrollment trends, (ii) our contracted backlog, which now includes a committed timeline for implementing our single largest new contract signed in 2020 in our pharmacy segment, and (iii) the growth of our sales pipeline across all segments of the business. In addition, we are excited about our October acquisition of Personica, and expect Personica revenue could grow at a rate materially faster than our other business lines, with further potential upside based on cross-selling efforts.
Looking farther ahead, in addition to the October 15, 2020 launch of our medication safety campaign (“Medication Safety Starts with a Pharmacist”) with the American Pharmacists Association, we have a number of exciting initiatives aimed at building greater awareness and, ultimately, revenue. Our MedWise™ science is attracting a high level of attention from pharmacists, state and national pharmacy associations, state boards of pharmacy, and the 60,000 student pharmacists in 145 schools of pharmacy in the U.S. Lastly, we see strong levels of interest and ongoing discussions with healthcare organizations recognizing the compelling value of MedWise™ as part of broader value-based agreements with employers, health plans, and government entities. Dr. Knowlton concluded, “As we exit 2020, we are encouraged by many of our leading indicators for future revenue growth in 2021 and beyond.”
Newbie...And anxious too.
Hope and wish SYME achieve the promised target . My boy's education will get sorted . Many thanks for the research, support and encouragement you LTH guys/gals. I am sure there will be many like me , going through this journey. ATB
??
The Company is targeting the end of the calendar year for completion of preliminary product evaluations, with full release of the final CE Marked system in Q1 2021 allowing for thorough clinical testing requirements."
"end of the calendar year " --- its hard but inevitable---WAITING
Knowing the future potential , background buying at a cheaper price...just a thought
No, unless forced to take it.
Even well researched vaccines over many years are known to have adverse effects..
Mask is the saviour...protect self , protect others .
About to roarrr...
Go go go...
https://businesscasestudies.co.uk/a-revolution-in-stock-monetization-supplyme/
https://www.google.com/amp/s/www.bbc.co.uk/news/amp/health-54000629
For anybody that want to research rather than listen to anonymous strangers opinions with a few posts..
March Float article..
https://www.thisismoney.co.uk/money/markets/article-8138543/STOCK-WATCH-Bad-time-float-Not-says-Italian-tech-firm-Supply-Me.html
Wallet investor ramp
https://walletinvestor.com/lse-stock-forecast/syme-stock-prediction
First Motley article
https://www.fool.co.uk/investing/2020/08/17/interested-in-the-supplyme-capital-share-price-heres-what-you-need-to-know/
Interview with CEO
https://ibsintelligence.com/podcasts/ep88-alessandro-zamboni-founder-chief-executive-officer-supplyme/
Securitisation
https://born2invest.com/articles/supplyme-capital-close-first-securitization/
Tech analysis
https://www.ii.co.uk/analysis-commentary/where-next-aim-newbie-supplyme-ii513246
Share buyers article
https://www.sharebuyers.co.uk/shares/supplyme-shares-going-for-growth-radical-shake-up-working-capital-access/
2nd Fool article - the hedge.
https://www.fool.co.uk/investing/2020/08/21/the-supplyme-capital-share-price-is-up-750-should-you-buy/
Directors dealing
https://www.sharebuyers.co.uk/shares/supplyme-chairman-buying-shares-director-dealing/
Inventory securitisation article
http://www.onc.hk/en_US/non-traditional-securitisation-inventory-securitisation/
Fintech Times article
https://thefintechtimes.com/three-interesting-fintech-partnerships-in-abu-dhabi/
In Business Article
https://www.thenational.ae/business/banking/italian-fintech-partners-with-abu-dhabi-company-on-scheme-to-offer-loans-1.1061822
Abu Dhabi article
https://www.crowdfundinsider.com/2020/08/165359-fintech-firm-supplyme-to-work-with-uaes-imass-llc-on-offering-lending-solutions-abu-dhabi-global-markets-also-working-on-financial-tech/amp/?__twitter_impression=true
Wall Street Journal article
https://www.wsj.com/articles/as-inventories-swell-companies-turn-to-novel-strategies-to-get-through-coronavirus-crisis-11596888000
UK Trading view - Long
https://uk.tradingview.com/chart/SYME/1sc0OMss-long-on-a-hunch/
II Most popular share
https://www.ii.co.uk/analysis-commentary/whos-and-whos-out-funds-trusts-and-shares-favour-ii513344
EPIC Article
https://www.proactiveinvestors.co.uk/companies/news/928276/supplyme-enters-alliance-with-italian-sme-fintech-marketplace-928276.html
Market watch article
https://www.marketwatch.com/press-release/why-must-investors-choose-the-supplyme-2020-09-07?reflink=mw_share_twitter
Express digest article
https://expressdigest.com/why-choose-supplyme-capital-stock-for-your-growing-business/
Share Talk article/Interview
https://www.share-talk.com/why-must-investors-choose-the-supplyme-capital-plc/
Pro active interview..
https://youtu.be/oNsB1YQ6i0M
Videos..
Company lists
https:
Trade view showing 'BUY'